Varian receives European approval for proton therapy system
22 February 2009
Varian Medical Systems (NYSE:VAR) has received the CE mark for its
Proton Therapy System, which is designed to help doctors to improve
treatments and outcomes in many cancer cases. With proton therapy,
doctors can use higher doses of radiation to control and manage tumours
while significantly reducing damage to healthy tissue and vital organs.
"CE mark is an important milestone in Varian’s initiative to develop
and market a compact system capable of intensity-modulated proton
therapy in single- or multi-room facilities,” said Lester Boeh, vice
president of emerging businesses for the company.
“This is a clear demonstration of our ongoing commitment to provide
the cancer treatment community and its patients with a clinically
practical and commercially viable proton therapy system that meets
accepted safety standards for medical equipment.”
The CE mark makes it possible for cancer treatment centres to begin
ordering, installing, and using the Varian Proton Therapy System in
regions where CE mark is required without having to obtain a
site-specific clearance to use this important technology.
“Varian is actively marketing the Varian Proton Therapy System, and
institutions from all parts of the world are pursuing this promising
technology for cancer patients in their regions,” Boeh said.
Through research and development and the acquisition of ACCEL in
Germany during 2007, Varian has developed a comprehensive proton therapy
system that utilizes the company’s technology for particle beam
generation, treatment planning, imaging, motion management, and
information management technology.
Bookmark this page